We are excited to share that Biocytogen will attend AET EU in Basel, Switzerland, from May 27th - 29th. Join us at Europe’s premier antibody event and elevate your expertise across discovery, engineering, and development. This year’s conference will feature a new track on “ADCs and Bioconjugates” to further innovation and increase efficacy.
What is AET?
AET (Antibody Engineering & Therapeutics) is a global, non-profit trade organization dedicated to supporting professionals and organizations engaged in antibody research and development. They host multiple major conferences around the world, gathering experts working towards revolutionizing antibody discovery and engineering.
Event Overview
Date: May 27th - 29th, 2026
Venue: Congress Center Basel, Messepl. 21, 4058 Basel, Switzerland
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s accelerate the trajectory of antibody discovery, we look forward to meeting you in Basel, Switzerland!
